

## Medical Coverage Policy | Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation



**EFFECTIVE DATE:** 02|01|2019  
**POLICY LAST UPDATED:** 07|21|2021

### OVERVIEW

Stroke prevention in atrial fibrillation (AF) is an important goal of treatment. Most embolic strokes originate from the left atrial appendage (LAA). Treatment with anticoagulant medications is the most common approach to stroke prevention. The Watchman™ device was approved by the U.S. Food and Drug Administration (FDA) for stroke prevention in patients with AF, and may offer a non-pharmacologic alternative to anticoagulant medications for the prevention of stroke in patients with AF.

### MEDICAL CRITERIA

#### Medicare Advantage Plans

Not applicable.

#### Commercial Products

The use of a device with FDA approval for percutaneous left atrial appendage closure (e.g., the Watchman) may be considered **medically necessary** for the prevention of stroke in patients with atrial fibrillation when the following criteria is met:

- There is an increased risk of stroke and systemic embolism based on CHADS2 score, **or** CHA2DS2-VASc score and;
- Systemic anticoagulation therapy is recommended, and;
- The long-term risks of systemic anticoagulation outweigh the risks of the device implantation

### PRIOR AUTHORIZATION

#### Medicare Advantage Plans

Not applicable

#### Commercial Products

Prior authorization is recommended and obtained via the online tool for participating providers. See Related Policies section.

### POLICY STATEMENT

#### Medicare Advantage Plans

Percutaneous left atrial appendage closure approved by the U.S. Food and Drug Administration (FDA) may be considered medically necessary for patients enrolled in a Centers for Medicare and Medicaid Services (CMS) approved clinical trial. Refer to Related Policy section.

**Note:** Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all BlueCHIP for Medicare policies. Therefore, BlueCHIP for Medicare policies may differ from Commercial products. In some instances, benefits for BlueCHIP for Medicare may be greater than what is allowed by the CMS.

#### Commercial Products

Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.

The use of other percutaneous left atrial appendage closure devices, including but not limited to the Lariat, <sup>5</sup> and Amplatzer, for stroke prevention in patients with atrial fibrillation is considered not medically necessary because these devices do not have FDA approval for LAA closure. In addition, the evidence is insufficient to determine the effects of the technology on health outcomes.

## COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable surgery benefits/coverage.

## BACKGROUND

Stroke is the most serious complication of atrial fibrillation (AF). The estimated incidence of stroke in nontreated patients with AF is 5% per year. Stroke associated with AF is primarily embolic, tends to be more severe than the typical ischemic stroke, and causes higher rates of mortality and disability. As a result, stroke prevention is a main goal of AF treatment.

Stroke in AF occurs primarily as a result of thromboembolism from the left atrium. The lack of atrial contractions in AF leads to blood stasis in the left atrium, and this low flow state increases the risk for thrombosis. The area of the left atrium with the lowest blood flow in AF, and, therefore, the highest risk of thrombosis, is the left atrial appendage (LAA). It has been estimated that 90% of left atrial thrombi occur in the LAA.

The main treatment for stroke prevention in AF is anticoagulation, which has proven efficacy. The risk for stroke among patients with AF is evaluated using several factors. Two commonly used scores, the CHADS<sub>2</sub> score and the CHADS<sub>2</sub>-VASc score are described below in Table 1. Warfarin is the predominant agent in clinical use. A number of newer anticoagulant medications, including dabigatran, rivaroxaban, and apixaban, have received U.S. Food and Drug Administration (FDA) approval for stroke prevention in nonvalvular AF and have demonstrated noninferiority to warfarin in clinical trials. While anticoagulation is effective for stroke prevention, it carries an increased risk of bleeding. Also, warfarin requires frequent monitoring and adjustments as well as lifestyle changes. Dabigatran does not require monitoring. However, unlike warfarin, the antithrombotic effects of dabigatran are not reversible with any currently available hemostatic drugs. Guidelines from the American College of Chest Physicians (2012) have recommended the use of oral anticoagulation for patients with AF who are at high risk of stroke (ie, CHADS<sub>2</sub> score  $\geq 2$ ), with more individualized choice of antithrombotic therapy in patients with lower stroke risk.

**Table 1. CHADS<sub>2</sub> and CHADS<sub>2</sub>-VASc Scores to Predict Ischemic Stroke Risk in Patients With Atrial Fibrillation**

Letter	Clinical Characteristics	Points Awarded
C	Congestive heart failure (signs/symptoms of heart failure confirmed with objective evidence of cardiac dysfunction)	1
H	Hypertension (resting blood pressure >140/90 mmHg on at least 2 occasions or current antihypertensive pharmacologic treatment)	1
A	Age $\geq 75$ y	2
D	Diabetes (fasting glucose >125 mg/dL or treatment with oral hypoglycemic agent and/or insulin)	1
S	Stroke or transient ischemic attack (includes any history of cerebral ischemia)	2
V	Vascular disease (prior myocardial infarction, peripheral arterial disease, or aortic plaque)	1
A	Age 65-74 y	1
Sc	Sex category of female (female sex confers higher risk)	1

Bleeding is the primary risk associated with systemic anticoagulation. Risk scores have been developed to estimate the risk of significant bleeding in patients treated with systemic anticoagulation, such as the HAS-BLED score, which has been validated to assess the annual risk of significant bleeding in patients with AF treated with warfarin.

The score ranges from 0 to 9, based on clinical characteristics, including the presence of hypertension, renal and liver function, history of stroke, bleeding, labile international normalized ratios, age, and drug/alcohol

use. Scores of 3 or greater are considered to be associated with high risk of bleeding, potentially signaling the need for closer monitoring of patients for adverse risks, closer monitoring of international normalized ratios, or differential dose selections of oral anticoagulants or aspirin.

Surgical removal, or exclusion, of the LAA is often performed in patients with AF who are undergoing open heart surgery for other reasons. Percutaneous left atrial appendage closure (LAAC) devices have been developed as a non-pharmacologic alternative to anticoagulation for stroke prevention in AF. The devices may prevent stroke by occluding the LAA, thus preventing thrombus formation.

Several versions of LAA occlusion devices have been developed. The Watchman Left Atrial Appendage System (Boston Scientific) is a self-expanding nickel titanium device. It has a polyester covering and fixation barbs for attachment to the endocardium. Implantation is performed percutaneously through a catheter delivery system, using venous access and transseptal puncture to enter the left atrium. Following implantation, patients receive anticoagulation with warfarin or alternative agents for approximately 1 to 2 months. After this period, patients are maintained on antiplatelet agents (ie, aspirin and/or clopidogrel) indefinitely. The Lariat Loop Applicator is a suture delivery device intended to close a variety of surgical wounds in addition to LAAC. The Cardioblate® closure device (Medtronic) is currently being tested in clinical studies. The Amplatzer cardiac plug (St. Jude Medical), is FDA-approved for closure of atrial septal defects but not for LAAC. A second-generation device, the Amplatzer Amulet, has been developed.

The Percutaneous LAA Transcatheter Occlusion device (ev3) has also been evaluated in research studies but has not received FDA approval. The Occlutech® (Occlutech) Left Atrial Appendage Occluder has received a CE mark for coverage in Europe.

The optimal study design for evaluating the efficacy of percutaneous LAAC for the prevention of stroke in AF is a randomized controlled trial that includes clinically relevant measures of health outcomes. The rate of ischemic stroke during follow-up is the primary outcome of interest, along with rates of systemic embolization, cardiac events, bleeding complications, and death. For the LAAC devices, the appropriate comparison group could be oral anticoagulation, no therapy (for patients who have a prohibitive risk for oral anticoagulation), or open surgical repair.

Although the Watchman device and other LAAC devices would ideally represent an alternative to oral anticoagulation for the prevention of stroke in patients with AF, during the postimplantation period, the device may be associated with increased thrombogenicity and, therefore, anticoagulation is used during the periprocedural period. Most studies evaluating the Watchman device have included patients who are eligible for anticoagulation.

In 2002, the PLAATO system (ev3 Endovascular) was the first device to be approved by FDA for LAA occlusion. The device was discontinued in 2007 for commercial reasons, and intellectual property was sold to manufacturers of the Watchman system.

In 2015, the Watchman™ Left Atrial Appendage Closure Technology (Boston Scientific) was approved by FDA through the premarket approval process by the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation (PROTECT AF) randomized controlled trial.

## **CODING**

### **Medicare Advantage Plans**

The following code(s) may be allowed as part of a CMS approved clinical study:

**33267** Exclusion of left atrial appendage, open, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) (New code as of 1/01/2022)

**33269** Exclusion of left atrial appendage, thoroscopic, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) (New code as of 1/01/2022)

**33340** Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation

**Note:** If you are treating a BlueCHiP for Medicare member as part of a CMS approved study, please follow the procedures for correct billing and coding of services found in the policy for Clinical Trials BlueCHiP for Medicare.

Claims for services rendered as part of a CMS approved clinical study must be billed with an appropriate modifier:

**Modifier Q0** – Investigational clinical service provided in a clinical research study that is in an approved research study (Medicare claims filed without the Q0 modifier will deny as not medically necessary)

**Modifier Q1** – Routine clinical service provided in a clinical research study that is in an approved clinical research study

### **Commercial Products**

The following code(s) is medically necessary when the criteria above has been met

**33267** Exclusion of left atrial appendage, open, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) (New code as of 1/01/2022)

**33269** Exclusion of left atrial appendage, thoracoscopic, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) (New code as of 1/01/2022)

**33340** Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation

### **RELATED POLICIES**

Clinical Trials Medicare Advantage Plans

Medicare Advantage Plans National and Local Coverage Determinations

Prior Authorization via Web-Based Tool for Procedures

### **PUBLISHED**

Provider Update, September 2021

Provider Update, December 2020

Provider Update, August 2019

Provider Update, November 2018

Provider Update, July 2017

### **REFERENCES**

1. National Coverage Determination (NCD) for PERCUTANEOUS Left Atrial Appendage Closure (LAAC) (20.34)

3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. Dec 2 2014;64(21):e1-76. PMID 24685669

4. Administration FaD. Approval Letter: WATCHMAN LAA Closure Technology. 2015; [http://www.accessdata.fda.gov/cdrh\\_docs/pdf13/p130013a.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf13/p130013a.pdf). Accessed June 1, 2015.

5. Holmes JDR, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. *J Am Coll Cardiol.* 2015;65(24):2614-2623. PMID
6. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial. *Circulation.* Feb 12 2013;127(6):720-729. PMID 23325525
7. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. *JAMA.* Nov 19 2014;312(19):1988-1998. PMID 25399274
8. Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. *J Am Coll Cardiol.* Apr 30 2013;61(17):1790-1798. PMID 23500276
9. FDA. 2013 Meeting Materials of the Circulatory System Devices Panel.2013; <http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/medicaldevices/medicaldevicesadvisorycommittee/circulatorysystemdevicespanel/ucm342357.htm>. Accessed May 5, 2015.
10. Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. *J Am Coll Cardiol.* Jul 8 2014;64(1):1-12. PMID 24998121
13. Matsuo Y, Sandri M, Mangner N, et al. Interventional closure of the left atrial appendage for stroke prevention. *Circ J.* Jan 11 2014;78(3):619-624. PMID 24419803
14. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). *J Am Coll Cardiol.* 2013;61(25):2551-2556. PMID
15. Chun KR, Bordignon S, Urban V, et al. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. *Heart Rhythm.* Dec 2013;10(12):1792-1799. PMID 23973952
16. Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. *J Am Coll Cardiol.* Aug 12 2014;64(6):565-572. PMID 25104525
17. Stone D, Byrne T, Pershad A. Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation. *Catheter Cardiovasc Interv.* Jul 2015;86(1):121-127. PMID 23765504
18. Lopez-Minguez JR, Eldoayen-Gragera J, Gonzalez-Fernandez R, et al. Immediate and one-year results in 35 consecutive patients after closure of left atrial appendage with the Amplatzer Cardiac Plug. *Rev Esp Cardiol.* Feb 2013;66(2):90-97. PMID 22939161
19. Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with nonvalvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. *EuroIntervention.* Oct 30 2014. PMID 25354761

20. Gloekler S, Shakir S, Doblies J, et al. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. *Clin Res Cardiol*. Aug 2015;104(8):656-665. PMID 25736061
21. Masoudi FA, Calkins H, Kavinsky CJ, et al. 2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview. *J Am Coll Cardiol*. Sep 29 2015;66(13):1497-1513. PMID 26133570
22. Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. *Eur Heart J*. Jan 27 2016. PMID 26822918
23. Chatterjee S, Herrmann HC, Wilensky RL, et al. Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device: A Systematic Review of Published Reports and Analytic Review of the FDA MAUDE Database. *JAMA Intern Med*. Jul 2015;175(7):1104-1109. PMID 25938303
24. Lakkireddy D, Afzal MR, Lee RJ, et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: Results from a US multicenter evaluation. *Heart Rhythm*. May 2016;13(5):1030-1036. PMID 26872554
25. Sahay S, Nombela-Franco L, Rodes-Cabau J, et al. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. *Heart*. Jan 15 2017;103(2):139-147. PMID 27587437
25. Li X, Wen SN, Li SN, et al. Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies. *Heart Rhythm*. Jun 2016;13(6):1203-1214. PMID 26724488
26. Wei Z, Zhang X, Wu H, et al. A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation. *Medicine (Baltimore)*. Aug 2016;95(31):e4382. PMID 27495048
27. Tereshchenko LG, Henrikson CA, Cigarroa J, et al. Comparative effectiveness of interventions for stroke prevention in atrial fibrillation: a network meta-analysis. *J Am Heart Assoc*. May 20 2016;5(5). PMID 27207998
28. Bajaj NS, Kalra R, Patel N, et al. Comparison of approaches for stroke prophylaxis in patients with nonvalvular atrial fibrillation: network meta-analyses of randomized controlled trials. *PLoS One*. 2016;11(10):e0163608. PMID 27706224
29. Hanif H, Belley-Cote EP, Alotaibi A, et al. Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. *J Cardiovasc Surg (Torino)*. Feb 17 2017. PMID 28215062

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.